Corona Remedies IPO Listing: Share of 1062 listed at 1470, check trading details before making new entry…

Corona Remedies IPO Listing: Shares of Corona Remedies, the second fastest growing pharmaceutical company in terms of domestic sales (Corona Remedies IPO Listing), made a strong entry in the domestic market today. Its IPO received a tremendous response from investors, with a total of more than 144 times bids received.

Shares were issued under the IPO at a price of ₹1062. Today, they were listed at ₹1,452.00 on BSE and ₹1,470.00 on NSE, which means IPO investors got a listing gain of about 38% ((Corona Remedies IPO Listing)).

However, the happiness of IPO investors quickly diminished when the shares fell. On NSE it fell to ₹ 1,432.50 (Corona Remedies IPO), which means that IPO investors are now earning 34.89% profit. Employees are even more profitable because they got a discount of ₹54 on each share.

Corona Remedies IPO got tremendous response.

The ₹655.37 crore IPO of Corona Remedies was open for subscription from December 8-10. This IPO received an overwhelming response from investors, and it was subscribed a total of 144.54 times.

The reserved portion for Qualified Institutional Buyers (QIBs) was subscribed 293.80 times (ex-anchor), Non-Institutional Investors (NIIs) 220.18 times, Retail Investors 30.39 times, and Employees 15.56 times.

The issue was entirely an offer-for-sale, with 6,171,101 shares of ₹10 face value sold through the offer-for-sale window. The proceeds from the offer-for-sale went to the selling shareholders, and because no new shares were issued under the issue, the company made no earnings.

About Corona Remedies

Corona Remedies, formed in August 2004, is a pharmaceutical company that manufactures products related to women’s health, cardiology, pain management, urology and other therapies. By June 2025, its portfolio will include 71 brands. Its marketing and distribution network is spread across the country.

It has 2,671 MRs in 22 states. It has two manufacturing facilities in Gujarat. The company’s strength is reflected in its position as the second fastest growing pharmaceutical company among the country’s 30 largest companies based on domestic sales.

The financial health of the company has continuously strengthened. In fiscal year 2023, it reported a net profit of ₹84.93 crore, which increased to ₹90.50 crore in fiscal year 2024 and ₹149.43 crore in fiscal year 2025. During this period, the company’s total income grew to ₹1,202.35 crore at a compound annual growth rate (CAGR) of more than 16%.

For the current fiscal year 2026, the company reported a net profit of ₹46.20 crore and total income of ₹348.56 crore in the first quarter (April-June 2025). ​​At the end of June 2025 quarter, the company had total debt of ₹106.65 crore, while reserves and surplus stood at ₹545.86 crore.